Table 1.
Baseline Clinicopathologic Characteristics of the Patients Treated with Sorafenib for Progressive RAI-Refractory DTC (n = 98)
| Median (IQR) or N (%) | |
|---|---|
| Age (years) | 65.6 (57.7–72.2) |
| ≥65 | 52 (53%) |
| Sex (male) | 30 (31%) |
| Pathology | |
| PTC | 67 (68%) |
| FTC | 18 (18%) |
| PDTC | 12 (12%) |
| PTC and FTC | 1 (1%) |
| Distant metastases | 98 (100%) |
| Time from diagnosis (years) | 9.1 (4.7–14.2) |
| Previous treatment | |
| RAI therapy | 98 (100%) |
| External beam radiation therapy | 37 (38) |
| Radiofrequency ablation | 6 (6%) |
| Systemic chemotherapy | 3 (3%) |
| Resection of metastatic tumor | 26 (27%) |
| Cumulative RAI dose (GBq) | 14.8 (7.7–22.2) |
| Metastatic lesion sites | |
| Lung | 96 (98%) |
| LNs | 54 (55%) |
| Bone | 36 (37%) |
| Pleura | 14 (14%) |
| Liver | 2 (2%) |
| Head and neck | 24 (24%) |
| Others (adrenal, kidney, pancreas, soft tissue) | 7 (7%) |
| Target lesions | |
| Lung | 75 (77%) |
| Bone | 11 (11%) |
| LNs | 12 (12%) |
| Head and neck | 10 (10%) |
| Others (adrenal, kidney, pancreas) | 5 (5%) |
| Definition of RAI refractoriness | |
| At least one target lesion without RAI uptake | 73 (74%) |
| RAI uptake, but progressive target lesions | 11 (11%) |
| Disease progression even with RAI therapy or cumulative RAI ≥22.3 GBq | 32 (33%) |
Data are presented as median (IQR) or n (%) unless indicated otherwise.
RAI, radioactive iodine; IQR, interquartile range; DTC, differentiated thyroid cancer; PTC, papillary thyroid cancer; FTC, follicular thyroid cancer; PDTC, poorly differentiated thyroid cancer; LN, lymph node.